Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: A real-life analysis
Frédéric Peyrade(Centre Hospitalier Universitaire de Nantes), Henri Montaudié(Hôpital l'Archet), J. Viotti(Centre Antoine Lacassagne), F. Brunet‐Possenti(Inserm), N. Dupin(Hôpital Cochin), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), P. Combemale(Centre Léon Bérard), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Caroline Robert(Institut Gustave Roussy), Alexandra Picard, G. Poissonnet, A.-B. Duval-Modeste(Inserm), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), A. Stefan(Centre Hospitalier Universitaire de Caen Normandie), Maria Kogay(Centre Antoine Lacassagne)
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k